Skip to main content
. Author manuscript; available in PMC: 2019 May 1.
Published in final edited form as: Metabolism. 2018 Jan 4;82:118–123. doi: 10.1016/j.metabol.2017.12.012

Figure 1. Comparison of ceramides between non-diabetic (black) and type 2 diabetic patients (gray) (mean ± SD).

Figure 1

Panel A: Comparison of ceramide species between diabetics and non-diabetics. Panel B: Comparison of total ceramides and total sphingosine between diabetics and non-diabetics. All values were normalized for protein content. Statistical significance (*= p<0.05) was assessed after adjustment for sex, age, and BMI. FFA = free-fatty acid, IMCL = intramyocellular lipids.